Zacks Research Has Negative Outlook of BDX FY2025 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Research analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $14.36 per share for the year, down from their prior forecast of $14.39. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.21 EPS, Q4 2026 earnings at $4.46 EPS, FY2026 earnings at $15.49 EPS and FY2027 earnings at $16.66 EPS.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.42 earnings per share.

Other analysts also recently issued reports about the stock. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Up 1.2 %

Shares of BDX stock opened at $240.19 on Wednesday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $248.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock’s 50 day simple moving average is $227.13 and its 200 day simple moving average is $232.70. The company has a market capitalization of $69.66 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 1.72 and a beta of 0.39.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Arete Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $767,000. Charles Schwab Investment Management Inc. boosted its holdings in Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Centre Asset Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $8,382,000. Nomura Asset Management Co. Ltd. increased its stake in shares of Becton, Dickinson and Company by 2.3% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock valued at $135,267,000 after acquiring an additional 12,845 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after acquiring an additional 673,568 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now directly owns 14,217 shares in the company, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,344 shares of company stock valued at $2,090,716. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.73%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.